The value of using next-generation flow cytometry to measure MRD status
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using next-generation flow cytometry to measure measurable residual disease (MRD) status. Dr Paiva comments on the advantages of using next-generation technologies, including the high sensitivity of these methods, and the possibility of performing MRD measurements without a bone marrow sample. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.